A
NRIX icon

AlphaQuest’s Nurix Therapeutics NRIX Stock Holding History

AlphaQuest’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-20,137
Closed -$382K – 1361
2025
Q4 		$382K Buy
20,137
+7,501
+59% +$108K 0.02% 1026
2025
Q3 		$117K Sell
12,636
-33,629
-73% -$349K 0.01% 1657
2025
Q2 		$527K Buy
46,265
+43,693
+1,699% +$472K 0.05% 572
2025
Q1 		$30.6K Sell
2,572
-4,413
-63% -$73.8K ﹤0.01% 1636
2024
Q4 		$132K Sell
6,985
-473
-6% -$10.8K 0.02% 1022
2024
Q3 		$168K Buy
7,458
+1,312
+21% +$29.7K 0.01% 1129
2024
Q2 		$128K Sell
6,146
-3,028
-33% -$47.2K 0.02% 870
2024
Q1 		$135K Buy
9,174
+3,449
+60% +$37.1K 0.02% 755
2023
Q4 		$59.1K Buy
+5,725
New +$39.2K 0.01% 863

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

AlphaQuest's NRIX Position: Q1 2026 in Review

AlphaQuest sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 20,137 shares — an estimated $382K sold.

AlphaQuest first reported a position in NRIX in Q4 2023 and held it in 9 quarters. The position peaked at $527K in Q2 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • AlphaQuest reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 20,137 Nurix Therapeutics shares in Q1 2026, an estimated $382K.
  • AlphaQuest first reported a position in Nurix Therapeutics in Q4 2023 and held it in 9 quarters.
  • AlphaQuest's Nurix Therapeutics position peaked at $527K in Q2 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.